/FGEN
FGEN Stock - FibroGen, Inc.
Healthcare|BiotechnologyNASDAQ
$8.60+3.37%
+$0.28 (+3.37%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.31
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+225.6%upside
Target: $28.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FGEN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.51 – $8.69
TARGET (TP)$28.00
STOP LOSS$7.91
RISK/REWARD1:28.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.75
52W High$21.95
52W Low$4.85
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $29.62M | $46.80M | $140.73M | $235.31M | $176.32M |
| Gross Profit | $14.06M | $42.84M | $120.45M | $-213,883,000 | $167.45M |
| Gross Margin | 47.5% | 91.5% | 85.6% | -90.9% | 95.0% |
| Operating Income | $-150,416,000 | $-322,721,000 | $-301,025,000 | $-288,530,000 | $-191,880,000 |
| Net Income | $-47,579,000 | $-284,232,000 | $-293,654,000 | $-290,023,000 | $-189,291,000 |
| Net Margin | -160.6% | -607.3% | -208.7% | -123.3% | -107.4% |
| EPS | $-0.48 | $-2.92 | $-3.15 | $-3.15 | $-2.11 |
Company Overview
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
57%
Hold / Neutral
2
29%
Sell / Underperform
1
14%
Analyst Consensus🟡 Mixed
4 Bullish3 Neutral/Bearish
Price Targets
$24
Average Target
↑ 179.1% Upside
Now
$2
Low
$24
Average
$35
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 8th 2023 | BofA Securities | Downgrade | Underperform | $2← $4 |
| June 26th 2023 | Stifel | Downgrade | Hold | - |
| June 26th 2023 | BofA Securities | Downgrade | Neutral | - |
| June 26th 2023 | Raymond James | Downgrade | Market Perform | - |
| June 26th 2023 | William Blair | Downgrade | Market Perform | - |
| June 2nd 2023 | Stifel | Upgrade | Buy | $32← $23 |
| January 31st 2023 | William Blair | Upgrade | Outperform | - |
| January 26th 2023 | Raymond James | Upgrade | Outperform | $35 |
| January 5th 2023 | BofA Securities | Upgrade | Buy | $27← $18 |
Earnings History & Surprises
FGENBeat Rate
50%
Last 18 quarters
Avg Surprise
+460.2%
EPS vs Estimate
Beats / Misses
9/8
1 met exactly
Latest EPS
$-1.61
Q4 2025
EPS Surprise History
Q1 24
-35.7%
$-0.57vs$-0.42
Q2 24
-6.5%
$-0.33vs$-0.31
Q3 24
+38.5%
$-0.16vs$-0.26
Q4 24
+55.3%
$-0.17vs$-0.38
Q1 25
0.0%
$-0.08vs$-0.08
Q2 25
-633.3%
$-4.00vs$0.75
Q3 25
-50.2%
$-3.38vs$-2.25
Q4 25
+59.9%
$-1.61vs$-4.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | $-3.89 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-4.01 | $-1.61 | +59.9% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-2.25 | $-3.38 | -50.2% | ✗ MISS |
Q2 2025 | May 12, 2025 | $0.75 | $-4.00 | -633.3% | ✗ MISS |
Q1 2025 | Mar 17, 2025 | $-0.08 | $-0.08 | 0.0% | = MET |
Q4 2024 | Nov 12, 2024 | $-0.38 | $-0.17 | +55.3% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.26 | $-0.16 | +38.5% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.31 | $-0.33 | -6.5% | ✗ MISS |
Q1 2024 | Feb 26, 2024 | $-0.42 | $-0.57 | -35.7% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-0.68 | $-0.52 | +23.5% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.72 | $-0.65 | +9.7% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.76 | $-0.81 | -6.6% | ✗ MISS |
Q1 2023 | Feb 27, 2023 | $-0.95 | $-0.70 | +26.3% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.83 | $-0.98 | -18.1% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.94 | $-0.78 | +17.0% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.84 | $-0.68 | +19.0% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.68 | $-1.45 | -113.2% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $0.01 | $0.54 | +9099.3% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.48 | $-1.45 | -202.1% | ✗ MISS |
Latest News
FibroGen shares are trading higher after the company announced that the Office of Orphan Products Development of the FDA has granted roxadustat Orphan Drug Designation for the treatment of myelodysplastic syndromes.
📈 PositiveBenzinga•Dec 15, 2025, 05:26 PM
FibroGen Wins FDA Orphan Drug Status for Blood Disorder Treatment Roxadustat
📈 PositiveBenzinga•Dec 15, 2025, 12:10 PM
CORRECTION: FibroGen Q3 EPS $(3.25) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate
➖ NeutralBenzinga•Nov 11, 2025, 12:25 AM
FibroGen Q3 EPS continuing operations $(3.50) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate
➖ NeutralBenzinga•Nov 10, 2025, 09:04 PM
HC Wainwright & Co. Reiterates Buy on FibroGen, Maintains $43 Price Target
📈 PositiveBenzinga•Sep 24, 2025, 02:25 PM
FibroGen Begins Phase 2 Trial Of New Prostate Cancer Drug FG-3246 With UCSF As First Site
📈 PositiveBenzinga•Sep 24, 2025, 11:03 AM
FibroGen shares are trading higher after the company announced regulatory approval for the sale of FibroGen China to AstraZeneca.
📈 PositiveBenzinga•Aug 18, 2025, 03:17 PM•Also:
FibroGen Confirms Regulatory Approval For Sale Of FibroGen International (Hong Kong) Ltd. To AstraZeneca Treasury Limited
📈 PositiveBenzinga•Aug 18, 2025, 11:11 AM•Also:
FibroGen to implement 1-for-25 reverse stock split; shares down 15%
📉 NegativeSeeking Alpha•Jun 12, 2025, 08:15 PM
Frequently Asked Questions about FGEN
What is FGEN's current stock price?
FibroGen, Inc. (FGEN) is currently trading at $8.60 per share. The stock has moved +3.37% today.
What is the analyst price target for FGEN?
The average analyst price target for FGEN is $28.00, based on 1 analyst.
What sector is FibroGen, Inc. in?
FibroGen, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is FGEN's market cap?
FibroGen, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does FGEN pay dividends?
No, FibroGen, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
XFOR
X4 Pharmaceuticals, Inc.
$3.60
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to FGEN for comparison